World Vision China Provided Most Needed Medical Equipment to Hospitals in Wuhan City

Total Page:16

File Type:pdf, Size:1020Kb

World Vision China Provided Most Needed Medical Equipment to Hospitals in Wuhan City World Vision China Provided Most Needed Medical Equipment to Hospitals in Wuhan City In March 2020, World Vision China provided 84 sets of most needed medical equipment to 3 key hospitals in Wuhan City of Hubei Province, to assist them in fighting against novel coronavirus, after learning their needs. The donation was made through China Charity Federation, under the guidance of the Medical Management Service Guidance Center, National Health Commission. The medial equipment included 30 bilevel positive airway pressure ventilators, 30 respiratory humidifiers and 24 ECG monitors, which were respectively received by 3 key hospitals: Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, West Campus of Wuhan Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Renmin Hospital of Wuhan University. Equipment would be put into service once finishing setting up. The Medical Management Service Guidance Center of the National Health Commission provided the specifications of the needed medical equipment and connected World Vision to the hospitals with the most needs. The Commission even sent staff to the hospitals to guide the receiving and usage of the equipment. “We must ensure hospitals have what patients need to survive as well as providing families with the means and knowledge to protect themselves from the spread of this potentially deadly virus," said World Vision China National Director, John Teng. To provide support for local departments in epidemic prevention and control work, as well as lower the risks of local children and communities being infected, World Vision China has already handed out nearly 50,000 masks to 5 counties – Luanping of Hebei Province, Baihe of Shaanxi Province, Honghe of Yunan Province, Duchang and Shicheng of Jiangxi Province; 2,000 bottles of alcohol disinfectants to social worker stations and area social work centers in Jiangmen, Yangjiang, Maoming, Zhanjiang of Guangdong Province; over 28,000 bottles of disinfectants to 8 areas – Shaanxi Province, Hebei Province, Tianjin City, Yunnan Province, Guizhou Province, Guangxi Zhuang Autonomous Region, Jiangxi Province, and Guangdong Province. World Vision also has disseminated personal epidemic prevention knowledge, which was published by official authorities, through World Vision's WeChat channel. Another 400,000 masks have been purchased by World Vision China from overseas and will be handed out to 10 areas -- Hunan Province, Shaanxi Province, Hebei Province, Gansu Province, Tianjin City, Yunnan Province, Guizhou Province, Guangxi Zhuang Autonomous Region, Jiangxi Province, and Guangdong Province. ▲ The doctor from Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, inspected and accepted the medical equipment. .
Recommended publications
  • The Functional Structure Convergence of China's Coastal Ports
    sustainability Article The Functional Structure Convergence of China’s Coastal Ports Wei Wang 1,2,3, Chengjin Wang 1,* and Fengjun Jin 1 1 Institute of Geographic Sciences and Natural Resources Research, CAS, Beijing 100101, China; [email protected] (W.W.); [email protected] (F.J.) 2 University of Chinese Academy of Sciences, Beijing 100049, China 3 School of Geography, Beijing Normal University, Beijing 100875, China * Correspondence: [email protected] Received: 6 September 2017; Accepted: 23 November 2017; Published: 28 November 2017 Abstract: Functional structure is an important part of a port system, and can reflect the resource endowments and economic development needs of the hinterland. In this study, we investigated the transportation function of coastal ports in China from the perspective of cargo structure using a similarity coefficient. Our research considered both adjacent ports and hub ports. We found that the transportation function of some adjacent ports was very similar in terms of outbound structure (e.g., Qinhuangdao and Huanghua) and inbound structure (e.g., Huanghua and Tangshan). Ports around Bohai Bay and the port group in the Yangtze River Delta were the most competitive areas in terms of outbound and inbound structure, respectively. The major contributors to port similarity in different regions varied geographically due to the different market demands and cargo supplies. For adjacent ports, the functional convergence of inbound structure was more serious than the outbound. The convergence between hub ports was more serious than between adjacent ports in terms of both outbound and inbound structure. The average similarity coefficients displayed an increasing trend over time.
    [Show full text]
  • Clinical Characteristics and Risk Factors for Developed COVID-19 Patients Transferring to Designated Hospital from Jianghan Fang
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.21.20074724; this version posted April 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Clinical Characteristics and Risk factors for developed COVID-19 patients transferring to designated hospital from Jianghan Fangcang shelter Hospital: a retrospective, observational study 1Yunfei Liao#, 2Yong Feng #, 3Bo Wang#, 1Hanyu Wang, 4Jinsha Huang, 5Yaxin Wu, 1Ziling Wu, 1Xiao Chen, 6Chao Yang, 7Xinqiao Fu and 1Hui Sun 1Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (Y Liao MD PhD, H Wang MD, Z Wu MD, X Chen MD, H Sun MD); 2Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (Y Feng MD PhD); 3Department of Rehabilitation, Wuhan No.1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (B Wang MD); 4Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (J Huang MD PhD); 5First Clinical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China (Y Wu BD) 6Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (C Yang MD PhD); 7Outpatient Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (X Fu PhD) # Contributed equally Correspondence to Hui Sun MD, Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Email: [email protected] 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Vaccines Currently in Development
    COVID-19 Treatment and Vaccine Tracker This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. TREATMENTS Current Type of FDA-Approved Clinical Trials for Funding Clinical Trials for Anticipated Next Number Developer/Researcher Stage of Published Results Sources Product - Treatment Indications Other Diseases Sources COVID-19 Steps Timing Development ANTIBODIES Begin Phase 1 trials in late TAK-888, antibodies from PhRMA spring. To patients between 1 recovered COVID-19 N/A Takeda Pre-clinical Wall Street Journal December 2020 and December patients Pink Sheet 2021 Biomedical Stat News Advanced MarketWatch Antibodies from mice, Research and Reuters 2 REGN3048-3051, against the N/A Regeneron Pre-clinical Start Phase 1 June 2020 Development Bloomberg News spike protein Authority FierceBiotech (BARDA) FiercePharma Antibodies from recovered Korea Herald 3 N/A Celltrion Pre-clinical Start Phase 1 in July 2020 COVID-19 patients UPI Antibodies from recovered BioSpace 4 N/A Kamada Pre-clinical COVID-19 patients AbbVie Stat News Antibodies from recovered 5 N/A Vir Biotech/WuXi Biologics/Biogen Pre-clinical Start Phase 1 ~ July 2020 Vir Biotech COVID-19 patients Vir Biotech Antibodies from recovered Lilly/Ab-Cellera (NIH Vaccines 6 N/A Pre-clinical Start Phase 1 in late July 2020 Endpoints News COVID-19 patients Research Center) * Indicates updated or new field This document contains an aggregation of publicly available information from validated sources. It is not an endorsement Copyright 2020 Updated April 2, 2020, at 2:30 p.m.
    [Show full text]
  • A Mirna-Based Signature Predicts Development of Disease Recurrence in HER2 Positive Breast Cancer After Adjuvant Trastuzumab- Based Treatment F
    www.nature.com/scientificreports OPEN Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab- based treatment F. Du, P. Yuan, Z. T. Zhao, Z. Yang, T. Wang, J. D. Zhao, Y. Luo, F. Ma, J. Y. Wang, Y. Fan, R. G. Cai, P. Zhang, Q. Li, Y. M. Song & B. H. Xu Scientific Reports 6:33825; doi: 10.1038/srep33825; published online 21 September 2016; updated on 14 October 2016 The Acknowledgements section in the PDF version of this Article is incorrect. “The following institutions participated in this study: Fudan University Shanghai Cancer Center; Zhejiang Cancer Hospital; Guangdong General Hospital; Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology; Nanfang Hospital, Southern Medical University; Sun Yat-Sen University Cancer Hospital; West China Hospital, Sichuan University; Harbin Medical University Cancer Hospital; Henan Cancer Hospital, Zhengzhou University; Peking Union Medical College Hospital. This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI14C0466), and funded by the Ministry of Health & Welfare, Republic of Korea (HI14C3344)”. should read: “The following institutions participated in this study: Fudan University Shanghai Cancer Center; Zhejiang Cancer Hospital; Guangdong General Hospital; Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology; Nanfang Hospital, Southern Medical University; Sun Yat-Sen University Cancer Hospital; West China Hospital, Sichuan University; Harbin Medical University Cancer Hospital; Henan Cancer Hospital, Zhengzhou University; Peking Union Medical College Hospital. This work was supported by Beijing Hope Run Special Fund (LC2013L09) and Capital Clinical Feature Applied Research Fund (Z141107002514010).
    [Show full text]
  • 2019年第3季度在韩国注册的中国水产企业名单the List of Chinese
    2019年第3季度在韩国注册的中国水产企业名单 The List of Chinese Registered Fishery Processing Establishments Export to Korea (Total 1347 , the third quarter of 2019,updated on 25 June, 2019) No. Est.No. 企业名称(中文) Est.Name 企业地址(中文) Est.Address 产品(Products) 北京市朝阳区崔各庄乡 The 23rd floor Sanyuan Property Jingmi Road 北京中洋环球金枪鱼有 1 1100/02010 Beijing Zhongyang Global Tuna Co.,Ltd 东辛店村京密路三元物 Dongxindian Village Cuigezhuang TownChaoyang Fishery Products 限公司 业院内23号楼 District Beijng 五洋海产(天津)有限 天津市塘沽区东江路 2 1200/02004 Ocean Products (Tian.Jin) Co., Ltd Dongjiang Road No.3849 Tanggu Tianjin Fishery Products 公司 3849号 欧盛实业(天津)有限 天津经济技术开发区渤 No.5, Bohai Road, Tianjin Economic & Technological 3 1200/02019 Ocean (Tianjin) Corporation Ltd. Fishery Products 公司 海路5号 Development Area, Tianjin 天津市颖明海湾食品有 天津市滨海新区中心渔 No.221 Yuehai RD., Binhai New Area Of The City 4 1200/02028 Tianjin Smart Gulf Foodstuffs Co.,Ltd. Fishery Products 限公司 港经济区悦海路221号 Center Fishing Port Economic Zone, Tianjin, China 天津市塘沽区海华水产 Tianjin Tanggu District Haihua Fishery Products Food 天津市塘沽区北塘镇水 No. 9, Shuichan Road, Beitang Town, Tanggu District, 5 1200/02048 Fishery Products 食品有限公司 Co., Ltd. 产路9号 Tianjin 天津百迅达进出口贸易 天津市津南区双桥河镇 South Dongnigu Village, Shuangqiaohe Town, Jinnan 6 1200/02063 Tianjin baixunda import and export trade Co., Ltd Fishery Products 有限公司 东泥沽村南 District, Tianjin, China 昌黎县筑鑫实业有限公 秦皇岛市昌黎县新开口 Economic Development Zone Xinkaikou Changli 7 1300/02228 Changli Zhuxin Enterprises Co., Ltd. Fishery Products 司 经济开发区 County Qinhuangdao 抚宁县渤远水产品有限 秦皇岛市抚宁县台营镇 Yegezhuang village taiying town funing county 8 1300/02229 Funing county boyuan aquatic products co.,ltd Fishery Products 公司 埜各庄村 Qinhuangdao city Hebei province 秦皇岛市江鑫水产冷冻 河北省秦皇岛北戴河新 Nandaihe Second District,Beidaihe New 9 1300/02236 Qinhuangdao Jiangxin Aquatic Food Products Co., Ltd.
    [Show full text]
  • Care of Pediatric Patients During COVID-19 Pandemic
    Care of Pediatric Patients during COVID-19 Pandemic Wuhan United “Living Through A Pandemic” Series 4 Co-organized with: Department of Pediatrics, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Forti & Consevage, P.C., Pennsylvania, USA Mead Johnson Nutrition, USA MEDICAL DISCLAIMER THIS PRESENTATION IS FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY AND MAY NOT BE CONSTRUED AS MEDICAL ADVICE. THE INFORMATION IS NOT INTENDED TO REPLACE MEDICAL ADVICE OFFERED BY PHYSICIANS. Contents 1. Opening remarks: Dr. Runming Jin 2. Diagnosis, Treatment and Prevention of COVID-19 in Children: Dr. Xiaoyan Wu 3. Management of Wards of Pediatric Hematological-Malignancy during COVID-19: Dr. Xiaoyan Wu 4. Protection for Medical Staff: Dr. Lei Li 5. Management of Children with other Non-COVID 19 related Health Care Needs: Dr. Lei Li Opening Remarks Runming Jin Clinical Professor, Department Chair Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Diagnosis, Treatment and Prevention of COVID-19 in Children Xiaoyan Wu MD, PhD, Associate Professor Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Information of Pediatric Patients in China • 2143 pediatric patients with COVID-19 were reported to the Chinese Center for Disease Control and Prevention from January 16 to February 8, 2020 • 731 (34.1%) laboratory-confirmed cases and 1412 (65.9%) suspected cases. • 1213 cases (56.6%) were boys. The age of disease onset ranged from 1.5m to 17y. • The median time from illness onset to diagnoses was 2 days (range: 0 to 42 days). • Of the 2143 pediatric patients, only one child died.
    [Show full text]
  • Curriculum Vitae Huiyun Xiang, M.D
    Curriculum Vitae Huiyun Xiang, M.D., M.P.H., Ph.D. Professional Address Home Address Center for Injury Research and Policy 4506 Bradford Road The Research Institute at Nationwide Children’s Hospital Upper Arlington, OH 43220 700 Children’s Drive Phone: (614) 459-8248 Columbus, OH 43205 Phone: (614) 355-2768 Fax: (614) 722-2448 Email: [email protected] Academic Education 1999 Ph.D. College of Veterinary Medicine and Biomedical Sciences Colorado State University Major: Injury Epidemiology 1991 M.P.H. School of Public Health Tongji Medical College Major: Health Statistics 1988 M.D. Tongji Medical College Major: Preventive Medicine Special Training 2006-2007 Upper Arlington Leadership Program City of Upper Arlington, Columbus, Ohio 2001-2002 Advanced Public Health Leadership Fellow Regional Institute for Health & Environmental Leadership Denver University 2000 Colorado Advanced Supervisory Leadership Training Colorado State Department of Personnel and Administration 1999 Colorado Supervisory Leadership Training Colorado State Department of Personnel and Administration Professional Employment Huiyun Xiang, MD MPH PhD - 2 - 2009-Present Associate Professor Associate Director of Professional Development Center for Injury Research and Policy The Research Institute at Nationwide Children’s Hospital Department of Pediatrics College of Medicine The Ohio State University 2003- 2008 Assistant Professor Associate Director of Professional Development Center for Injury Research and Policy The Research Institute at Nationwide Children’s
    [Show full text]
  • (TJDBPS01): Study Protocol for a Multicenter Randomized Controlled Trial
    Total laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy (TJDBPS01): study protocol for a multicenter randomized controlled trial. Hang Zhang1, Junfang Zhao1, Yechen Feng1, Rufu Chen2, Xuemin Chen3, Wei Cheng4, Dewei Li5, Jingdong Li6, Xiaobing Huang7, Heguang Huang13, Deyu Li14, Jing Li7, Jianhua Liu8, Jun Liu9, Yahui Liu10, Zhijian Tan11, Xinmin Yin4, Wenxing Zhao12, Yahong Yu1, Min Wang1✉, Renyi Qin1 ✉. Minimally Invasive Pancreas Treatment Group in the Pancreatic Disease Branch of China’s International Exchange and Promotion Association for Medicine and Healthcare. 1 Department of Biliary–Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. 2 Department of Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. 3 Department of Pancreaticobiliary Surgery, The Third Affiliated Hospital of Soochow University, Jiangsu 213000, China. 4 Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410000, China. 5 Department of Hepatobiliary Surgery, First Affiliated Hospital of Chongqing Medical University, Chongqing 404100, China. 6 Department of Pancreatico-Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Sichuan 637000, China. 7 Department of Pancreatico-Hepatobiliary Surgery, The Second Affiliated Hospital, Army Medical University, PLA, Chongqing 404100, China. 8 Department of Hepato–Pancreato–Biliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, China. 9 Department of Hepato–Pancreato–Biliary Surgery, Shandong Provincial Hospital, Shandong 250000, China. 10 Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, Jilin 130021, China. 11 Department of Hepatobiliary and Pancreatic Surgery, Guangdong Province Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, China.
    [Show full text]
  • Exploring the Chinese Metal Scene in Contemporary Chinese Society (1996-2015)
    "THE SCREAMING SUCCESSOR": EXPLORING THE CHINESE METAL SCENE IN CONTEMPORARY CHINESE SOCIETY (1996-2015) Yu Zheng A Thesis Submitted to the Graduate College of Bowling Green State University in partial fulfillment of the requirements for the degree of MASTER OF ARTS December 2016 Committee: Jeremy Wallach, Advisor Esther Clinton Kristen Rudisill © 2016 Yu Zheng All Rights Reserved iii ABSTRACT Jeremy Wallach, Advisor This research project explores the characteristics and the trajectory of metal development in China and examines how various factors have influenced the localization of this music scene. I examine three significant roles – musicians, audiences, and mediators, and focus on the interaction between the localized Chinese metal scene and metal globalization. This thesis project uses multiple methods, including textual analysis, observation, surveys, and in-depth interviews. In this thesis, I illustrate an image of the Chinese metal scene, present the characteristics and the development of metal musicians, fans, and mediators in China, discuss their contributions to scene’s construction, and analyze various internal and external factors that influence the localization of metal in China. After that, I argue that the development and the localization of the metal scene in China goes through three stages, the emerging stage (1988-1996), the underground stage (1997-2005), the indie stage (2006-present), with Chinese characteristics. And, this localized trajectory is influenced by the accessibility of metal resources, the rapid economic growth, urbanization, and the progress of modernization in China, and the overall development of cultural industry and international cultural communication. iv For Yisheng and our unborn baby! v ACKNOWLEDGMENTS First of all, I would like to show my deepest gratitude to my advisor, Dr.
    [Show full text]
  • Spatial and Temporal Characteristics of 2014 Dengue Outbreak
    www.nature.com/scientificreports OPEN Spatial and Temporal Characteristics of 2014 Dengue Outbreak in Guangdong, China Received: 23 August 2017 Mattia Sanna 1, Jianyong Wu2,3,4,5, Yanshan Zhu2,3,4,5, Zhicong Yang6, Jiahai Lu2,3,4,5 & Accepted: 22 December 2017 Ying-Hen Hsieh1,7 Published: xx xx xxxx The record-breaking number of dengue cases reported in Guangdong, China in 2014 has been topic for many studies. However, the spatial and temporal characteristics of this unexpectedly explosive outbreak are still poorly understood. We adopt an integrated approach to ascertain the spatial- temporal progression of the outbreak in each city in Guangdong as well as in each district in Guangzhou, where the majority of cases occurred. We utilize the Richards model, which determines the waves of reported cases at each location and identifes the turning point for each wave, in combination with a spatial association analysis conducted by computing the standardized G* statistic that measures the degree of spatial autocorrelation of a set of geo-referenced data from a local perspective. We found that Yuexiu district in Guangzhou was the initial hot spot for the outbreak, subsequently spreading to its neighboring districts in Guangzhou and other cities in Guangdong province. Hospital isolation of cases during early stage of outbreak in neighboring Zhongshan (in efort to prevent disease transmission to the vectors) might have played an important role in the timely mitigation of the disease. Integration of modeling approach and spatial association analysis allows us to pinpoint waves that spread the disease to communities beyond the borders of the initially afected regions.
    [Show full text]
  • Annual Report 2020 03 Corporate Information
    Our Vision Dedicate to become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market. Our Mission Better health for families worldwide. 02 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Contents 04 Corporate Information 07 Financial Highlights 08 Chairman’s Statement 12 Management Discussion and Analysis 67 Five-Year Statistics 68 Report of the Directors 91 Supervisory Committee Report 93 Corporate Governance Report 104 Environmental, Social and Governance Report 135 Biographical Details of Directors, Supervisors and Senior Management 144 Independent Auditor’s Report 149 Consolidated Statement of Profit or Loss 150 Consolidated Income Statement 151 Consolidated Statement of Financial Position 153 Consolidated Statement of Changes in Equity 155 Consolidated Statement of Cash Flows 157 Notes to Financial Statements 276 Definitions Annual Report 2020 03 Corporate Information Directors Authorized Representatives Executive Director Mr. Wu Yifang (吳以芳)11 Mr. Wu Yifang (吳以芳) Ms. Kam Mei Ha Wendy (甘美霞) (Chairman1 and Chief Executive Officer) Mr. Chen Qiyu (陳啟宇)12 Non-executive Directors Strategic Committee Mr. Chen Qiyu (陳啟宇)2 Mr. Chen Qiyu (陳啟宇) (Chairman) Mr. Yao Fang (姚方)3 Mr. Wu Yifang (吳以芳) Mr. Xu Xiaoliang (徐曉亮) Mr. Yao Fang (姚方) Mr. Gong Ping (龔平)4 Mr. Xu Xiaoliang (徐曉亮) Mr. Pan Donghui (潘東輝)4 Ms. Li Ling (李玲) Mr. Zhang Houlin (張厚林)5 Mr. Liang Jianfeng (梁劍峰)6 Audit Committee Mr. Wang Can (王燦)7 Ms. Mu Haining (沐海寧)9 Mr. Tang Guliang (湯谷良) (Chairman) Mr. Jiang Xian (江憲) Independent Non-executive Directors Mr. Gong Ping (龔平)4 Mr. Jiang Xian (江憲) Mr. Wang Can (王燦)7 Dr. Wong Tin Yau Kelvin (黃天祐) Ms.
    [Show full text]
  • A Collaborative Online AI Engine for CT-Based COVID-19 Diagnosis
    medRxiv preprint doi: https://doi.org/10.1101/2020.05.10.20096073; this version posted May 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . 1 A collaborative online AI engine for CT-based COVID-19 diagnosis 2 3 Yongchao Xu1,2#, Liya Ma1#, Fan Yang3#, Yanyan Chen4#, Ke Ma2, Jiehua Yang2, Xian Yang2, Yaobing 4 Chen 5, Chang Shu2, Ziwei Fan2, Jiefeng Gan2, Xinyu Zou2, Renhao Huang2, Changzheng Zhang6, 5 Xiaowu Liu6, Dandan Tu6, Chuou Xu1, Wenqing Zhang2, Dehua Yang7, Ming-Wei Wang7, Xi Wang8, 6 Xiaoliang Xie8, Hongxiang Leng9, Nagaraj Holalkere10, Neil J. Halin10, Ihab Roushdy Kamel11, Jia Wu12, 7 Xuehua Peng13, Xiang Wang14, Jianbo Shao13, Pattanasak Mongkolwat15, Jianjun Zhang16,17, Daniel L. 8 Rubin18, Guoping Wang 5, Chuangsheng Zheng3*, Zhen Li1*,Xiang Bai2*, Tian Xia2,5* 9 1Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and 10 Technology, Wuhan 430030, China. 11 2School of Electronic Information and Communications, Huazhong University of Science and Technology, Wuhan 12 430074, China. 13 3Department of Radiology, Union Hospital of Tongji Medical College, Huazhong University of Science and 14 Technology, Wuhan 430022, China. 15 4Department of Information Management, Tongji Hospital, Huazhong University of Science and Technology, 16 Wuhan 430030, China. 17 5Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 18 Wuhan 430030, China. 19 6HUST-HW Joint Innovation Lab, Wuhan 430074, China.
    [Show full text]